General Atlantic makes strategic investment in Synaptive Medical

8 November 2016 (Last Updated November 8th, 2016 18:30)

Canadian medical device company Synaptive Medical has received strategic investment from equity firm General Atlantic.

Canadian medical device company Synaptive Medical has received strategic investment from equity firm General Atlantic.

This will help Synaptive to accelerate commercialisation of its BrightMatter suite of products.

The investment is also expected to assist Synaptive in new research and product development.

The BrightMatter products are designed to provide advanced visual and information tools to enable surgeons to focus on patient outcomes.

Synaptive Medical president Cameron Piron said: “The healthcare industry is shifting toward an integrated delivery model that treats the whole patient from the diagnosis to surgery and beyond.

“Efficient medical imaging, combined with timely and effective care, is a critical driver of that change.

"Synaptive is developing novel imaging solutions that will help improve clinical outcomes for patients in partnership with the people and institutions that care for them.

“Partnering with an outstanding investor such as General Atlantic demonstrates our commitment to long-term growth.

"We look forward to leveraging GA’s deep healthcare expertise and strong track record backing high-growth companies.”

Synaptive has cleared its products for clinical use through the review processes of the US Food and Drug Administration (FDA) and Health Canada, beginning with BrightMatter Plan, its surgical planning tool, which secured approval in early 2014 and continuing with approval of more complex surgical navigation and visualization systems.

In four years, Synaptive has introduced five Class-II and three Class-I medical devices in the US and an equivalent number of products in Canada.

"Efficient medical imaging, combined with timely and effective care, is a critical driver of that change."

ImageDrive, Synaptive’s flagship informatics platform, received FDA approval in early 2016.

Synaptive acquired intellectual property and products from ClearCanvas, a developer of innovative imaging informatics solutions last year.

ClearCanvas technology is the architectural backbone for Synaptive’s BrightMatter products, including BrightMatter Plan, and currently has approximately 60,000 worldwide users.


Image: Some of Synaptive’s BrightMatter products. Photo: © Synaptive Medical.